<DOC>
	<DOCNO>NCT00293358</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , etoposide , ifosfamide , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving one drug ( combination chemotherapy ) radiation therapy may kill tumor cell . PURPOSE : This phase III trial study combination chemotherapy follow radiation therapy see well work compare radiation therapy alone treat patient germ cell tumor brain .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Germ Cell Tumors Brain</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate compare , non-randomized protocol , reduced-dose craniospinal radiotherapy alone combination chemotherapy comprise carboplatin , etoposide phosphate , ifosfamide local irradiation patient intracranial germinoma . - Increase survival combination chemotherapy comprise cisplatin , etoposide phosphate , ifosfamide follow focal radiotherapy craniospinal irradiation patient intracranial secrete germ cell tumor . Secondary - Use diagnostic protocol image laboratory investigation , , treatment . - Establish use common documentation system regard general patient 's data , include diagnostic test , clinical evaluation , surgery , histology , radiotherapy , chemotherapy , toxicity . - Collect information toxicity , prognostic factor , tumor marker . - Collect epidemiological data , include documentation incidence site histologic pattern intracranial secrete nonsecreting germ cell tumor child adolescent . - Register associate malformation patient well epidemiology tumor malformation relative . OUTLINE : This non-randomized , multicenter study . Patients stratify accord tumor classification ( pure CNS germinoma v secrete germ cell tumor embryonal carcinoma ) . Patients stratum I undergo biopsy surgical resection begin radiotherapy without chemotherapy . - Stratum I ( pure CNS germinoma [ without elevated marker ] ) : Patients receive 1 2 treatment option base national/center standard : - Option 1 : Patients receive reduced-dose craniospinal radiotherapy 5 day week 3 week follow boost tumor bed 5 day week 2 week . Patients multifocal metastatic disease receive additional boost tumor site . - Option 2 : Patients receive carboplatin IV 1 hour day 1 , etoposide phosphate IV 1 hour day 1-3 22-24 , ifosfamide IV 3 hour day 22-26 . Treatment repeat every 6 week 2 course . After recovery chemotherapy , patient undergo radiotherapy 5 day week 5 week . - Stratum II ( secrete tumor embryonal carcinoma ) : Patients receive etoposide phosphate IV 1 hour day 1-3 , cisplatin IV 1 hour day 1-5 , ifosfamide IV 22 hour day 1-5 . Treatment repeat every 3 week 4 course . Patients whose tumor marker return normal completion chemotherapy protocol . Patients may undergo surgery chemotherapy course 2 4 require . After completion chemotherapy recovery surgery , patient nonmetastatic disease undergo radiotherapy tumor bed 5 day week 6 week , patient metastatic disease undergo radiotherapy cerebrum , spinal axis , tumor bed 7 week . After completion study treatment , patient follow 4 week periodically . PROJECTED ACCRUAL : Approximately 500 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Clinical radiological evidence intracranial germ cell tumor , classify 1 following : Germinoma Pure germinoma Germinoma mature and/or immature teratoma Secreting germ cell tumor Elevated tumor marker serum and/or cerebral spinal fluid evidence follow : Alphafetoprotein &gt; 25 ng/mL βhuman choriogonadotropin &gt; 50 IU/L Any tumor contain 1 component : Yolk sac tumor Choriocarcinoma Embryonal tumor Normal tumor marker allow Diagnosis confirm histology elevate serum marker Metastatic nonmetastatic disease Two separate tumor suprasellar pineal area without evidence metastatic disease elsewhere consider nonmetastatic multifocal disease Study treatment must begin ≤ 4 week diagnosis No pure immature mature teratomas The following additional patient eligible : Patients &gt; 18 year age provide appropriate protocol exist Patients diagnose &gt; 4 week ago Patients relapse PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : No prior treatment except surgery No concurrent amino glycoside nephrotoxic drug ifosfamide administration No concurrent growth factor No concurrent chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>childhood central nervous system choriocarcinoma</keyword>
	<keyword>childhood central nervous system embryonal tumor</keyword>
	<keyword>childhood central nervous system yolk sac tumor</keyword>
</DOC>